[Children with acute lymphoblastic leukemia: prognostic significance of polymerase-chain-reaction analysis of minimal residual disease]. 1996

E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
Centraal Laboratorium van de Bloedtransfusiedienst, Amsterdam.

OBJECTIVE Determination of the usefulness of polymerase chain reaction (PCR) for the detection of minimal residual disease (MRD) in bone marrow in children suffering from progenitor-B cell acute lymphoblastic leukaemia during and after treatment. METHODS Descriptive. METHODS Emma's Children's Hospital, Academic Medical Centre, University of Amsterdam and Central Laboratory of the Dutch Red Cross, Amsterdam. METHODS Of 50 children suffering from progenitor-B cell ALL, stored bone marrow samples and bone marrow slides were investigated: 328 bone marrow samples were analysed by PCR for IgH/TCR delta; 34 patients were analysed at the end of induction therapy. Follow-up period was 20 to 133 months. RESULTS Twenty-two patients stayed in continuous complete remission (CCR), 28 patients experienced a recurrence (REC). Reduction of tumour mass was higher in the CCR group. At the end of induction therapy 2/18 CCR patients and 10/16 REC patients were PCR positive (p = 0.005). PCR positivity was not related with known prognostic factors. After recurrence 6/8 patients, who became PCR negative, stayed in remission. All patients who stayed positive after treatment for their recurrence died from leukaemia (p = 0.006). All children who were only temporary PCR negative suffered a recurrence. CONCLUSIONS Analysis of MRD by means of PCR on bone marrow samples during and after treatment for progenitor-B cell ALL is of prognostic importance.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D016692 Receptors, Antigen, T-Cell, gamma-delta T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see ANTIGENS, CD3). Antigen Receptors, T-Cell, gamma-delta,T-Cell Receptors delta-Chain,T-Cell Receptors gamma-Chain,T-Cell Receptors, gamma-delta,TcR gamma-delta,Antigen T Cell Receptor, delta Chain,Antigen T Cell Receptor, gamma Chain,Receptors, Antigen, T Cell, gamma delta,T Cell Receptors, gamma delta,T-Cell Receptor delta-Chain,T-Cell Receptor gamma-Chain,T-Cell Receptor, gamma-delta,T Cell Receptor delta Chain,T Cell Receptor gamma Chain,T Cell Receptor, gamma delta,T Cell Receptors delta Chain,T Cell Receptors gamma Chain,TcR gamma delta,delta-Chain, T-Cell Receptor,delta-Chain, T-Cell Receptors,gamma-Chain, T-Cell Receptor,gamma-Chain, T-Cell Receptors,gamma-delta T-Cell Receptor,gamma-delta T-Cell Receptors,gamma-delta, TcR
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma
D018365 Neoplasm, Residual Remnant of a tumor or cancer after primary, potentially curative therapy. Minimal Residual Disease,Residual Cancer,Residual Tumor,Minimal Disease, Residual,Residual Disease, Minimal,Residual Neoplasm,Residual Tumour,Cancer, Residual,Minimal Residual Diseases,Residual Cancers,Residual Minimal Disease,Residual Minimal Diseases,Residual Neoplasms,Residual Tumors,Residual Tumours,Tumour, Residual

Related Publications

E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
November 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
January 2015, Revista brasileira de hematologia e hemoterapia,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
March 2010, Zhonghua er ke za zhi = Chinese journal of pediatrics,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
January 2015, Revista brasileira de hematologia e hemoterapia,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
August 1991, Blood,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
November 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
February 2003, Journal of pediatric hematology/oncology,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
May 2004, Leukemia,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
January 1992, Leukemia,
E J Steenbergen, and O J Verhagen, and H van den Berg, and E F van Leeuwen, and A E von dem Borne, and C E van der Schoot
January 1991, Blood,
Copied contents to your clipboard!